In the past twelve months, regenerative medicine investments gained momentum, as new and promising clinical data got released. The momentum has been growing in recent years, enabling the cell therapy and genome editing sectors to evolve into a global industry.
The mesenchymal stem cell industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about mesenchymal stem cell industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant mesenchymal stem cell industry events for July 2015.
July is National Cord Blood Awareness Month. It is a time during which the importance of cord blood and tissue stem cells is celebrated. Importantly, hematopoietic stem cells (HSCs) from cord blood can now be used to treat more than 80 diseases and conditions. Mesenchymal stem cells present in cord tissue are also being explored in a wide range of clinical trials.
Cord Blood Awareness
There are three primary categories of people who need to increase their awareness about the importance of cord blood stem cells. These categories include:
- Expectant (pregnant) parents
- Extended support networks for parents, including brothers, sisters, grandparents, aunts, uncles and friends
- Medical practitioners, including nurses and Ob/Gyns
July 14, 2015, COLOGNE, Germany—Axiogenesis AG, a leading supplier of tissue-specific human cell types derived from induced pluripotent stem cells (iPSCs), and provider of pre-clinical drug development assays and disease models, announced today that it has signed an sublicense agreement with GE Healthcare (GEHC). Under the agreement, GEHC will sublicense intellectual property to use human iPSCs, enabling Axiogenesis to develop cellular assays and models derived from stem cells for use in drug discovery and toxicity screening for its customers. This agreement strengthens Axiogenesis’ ability to offer the market freedom-to-operate with Axiogenesis’ proprietary iPSC-derived cells and tissues.